News/Events

Our transient mammalian cell expression system can be used to produce functional fusion proteins with extended in vivo half-life for use in pre-clinical proof of concept (POC) studies, through selection of an appropriate fusion partner.

There are many variables to consider when producing novel recombinant proteins.  These variables include selection of an expression system, construct design, and scale.  In the upcoming months, we will focus on the use of fusion proteins for recombinant protein expression in mammalian cell systems including purpose, selection, placement, and removal.

There are many variables to consider when producing novel recombinant proteins.  Here we will focus on the importance of performing small-scale expression optimization.

“You cannot get through a single day without having an impact on the world around you.” – Jane Goodall

There are many variables to consider when producing novel recombinant proteins, and for those with no prior precedent for recombinant protein production, it may be beneficial to generate multiple variants of a protein construct. 

You don’t need a four-leaf clover to have good luck with your recombinant protein production. Make your own luck. Contact Proteos today for protein expression and purification services that are customized to fit your needs.

Proteos has secured a discounted registration fee for you to attend the PEGS Summit in Boston, MA. Register today and take $150 off the current rate.

Proteos is an industry leader in the production of high-quality recombinant proteins from multiple expression platforms. One of the first variables to consider when producing recombinant proteins is the optimal expression system.

There are many variables to consider when producing novel recombinant proteins.  These variables include selection of an expression system, construct design, and scale.

Thank you to our valued customers for your business and support in 2021. We wish you a joyous holiday season and look forward to working with you in 2022.